Bactobio

Bactobio is a private, pre-revenue platform biotechnology company targeting the discovery of novel antimicrobials from uncultured microbes. Its core innovation is a two-part platform combining a Microbial Generation Platform, which uses co-culture strategies, automation, and synthetic biology to grow novel microbial species, with a Discovery Platform that screens these microbes for bioactive compounds against specific pathogens. With a seasoned team and notable advisors, the company aims to address the critical global challenges of antimicrobial resistance and sustainable agriculture by accessing an entirely new frontier of natural product chemistry.

Integrated platform combining a Microbial Generation Platform (using NGS, DoE, automation, and synthetic biology to culture novel microbes from environmental samples) and a Discovery Platform (using bioinformatics, high-throughput screening, and chemoinformatics to identify novel antimicrobial metabolites).

Bactobio competes in the emerging field of 'microbial dark matter' mining, facing competition from other biotech startups (e.g., Hexagon Bio, Lodo Therapeutics) as well as the natural product discovery units of large pharma and agri-tech companies. Its differentiation hinges on the claimed efficiency and scale of its integrated cultivation and screening platform.